{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:25:32Z","timestamp":1780687532168,"version":"3.54.1"},"reference-count":110,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Most malignant hematological diseases are generally a consequence of acquired mutations or rearrangements in cell replication processes. Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease that results from acquired genetic and epigenetic alterations in hematopoietic progenitor cells. Despite the advances made in understanding the pathogenesis of this disease, the overall survival of patients remains very low due to the high relapse rate. Pharmacogenetics and massive sequencing studies have allowed the identification of new recurrent mutations with significant prognostic impact in AML; furthermore, it seems likely that whole genome sequencing will soon become a standard diagnostic test, which will allow the molecular diagnosis of patients. Therefore, it is necessary to develop molecular targets that open new therapeutic perspectives and allow individualized treatment of patients with this aggressive disease. Chronic myeloid leukemia (CML) is the first neoplastic disease for which a characteristic genetic alteration was described. It has, by definition, a genetic marker, the BCR::ABL1 rearrangement, as a consequence of the t9;22(q34;q11) translocation. Its study is essential for the diagnosis of this entity and also for monitoring the response to treatment. Drugs known as tyrosine kinase inhibitors (TKIs) that target the BCR::ABL1 protein (oral targeted therapy) are the conventional treatment of CML, representing a change of paradigm in the management of oncohematological patients.<\/jats:p>","DOI":"10.3390\/jpm12101607","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:09:29Z","timestamp":1664492969000},"page":"1607","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-1050","authenticated-orcid":false,"given":"Carolina","family":"Alarc\u00f3n-Payer","sequence":"first","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Del Mar","family":"S\u00e1nchez Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Mart\u00edn Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Puerta Puerta","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica Hematolog\u00eda y Hemoterapia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Jim\u00e9nez Morales","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"1497","article-title":"A minute chromosome in human chronic granulocitic leukaemia","volume":"32","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"ref_4","unstructured":"American Cancer Society (2022). Cancer Facts and Figures 2022, American Cancer Society. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2022.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: An update","volume":"94","author":"Sandin","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.1990.tb07832.x","article-title":"A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia","volume":"76","author":"Cervantes","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood.V72.2.485.485","article-title":"Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia","volume":"72","author":"Shtalrid","year":"1988","journal-title":"Blood"},{"key":"ref_8","unstructured":"Moraleda Jim\u00e9nez, J.M. (2017). Leucemias. Concepto y clasificaci\u00f3n. Leucemias agudas. Pregrado de hematolog\u00eda, Sociedad Espa\u00f1ola de Hematolog\u00eda y Hematoterapia. [4th ed.]."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.21234","article-title":"Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome","volume":"15","author":"Meyers","year":"2005","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.2021011722","article-title":"How I treat chronic-phase chronic myelogenous leukemia","volume":"139","author":"Berman","year":"2022","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41375-021-01164-x","article-title":"Two decades of targeted therapies in acute myeloid leukemia","volume":"35","author":"Cucchi","year":"2021","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3324\/haematol.2021.279317","article-title":"Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: Toward gene expression-based biomarkers","volume":"107","author":"Krishnan","year":"2022","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.therap.2021.11.003","article-title":"Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription","volume":"77","author":"Maillard","year":"2022","journal-title":"Therapie"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/13543784.2021.1941863","article-title":"Asciminib. An investigational agent for the treatment of chronic myeloid leukemia","volume":"30","author":"Breccia","year":"2021","journal-title":"Expert Opin. Investig. Drugs."},{"key":"ref_16","first-page":"357027","article-title":"Imatinib: A Breakthrough of Targeted Therapy in Cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Rese Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-319-91439-8_2","article-title":"Dasatinib","volume":"212","author":"Lindauer","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: A novel, selective tyrosine kinase inhibitor","volume":"1","author":"Blay","year":"2011","journal-title":"Semin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1517\/14656566.2014.882898","article-title":"Bosutinib: A review of preclinical and clinical studies in chronic myelogenous leukemia","volume":"15","author":"Rusconi","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_20","first-page":"1111","article-title":"Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia","volume":"20","author":"Price","year":"2013","journal-title":"Onco Targets Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","article-title":"Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse","volume":"34","author":"Ravandi","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12438","article-title":"TP53mutations andMDM2(SNP309) identify subgroups of AML patients with impaired outcome","volume":"94","author":"Falk","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Khan, M., Corte, J., Kadia, K., Brandt, M., Pierce, S., Pate, K.P., and Borthakur, G. (2017). Clinical outcomes and co-occurring mutations in patients with RUNX1-mutated acute myeloid leukemia. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081618"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of Relapsed\/Refractory Acute Myeloid Leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 Inhibitors in acute myeloid leukemia: Current status and future directions","volume":"16","author":"Baer","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","article-title":"FLT3 inhibitors in acute myeloid leukemia","volume":"4","author":"Wu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_32","unstructured":"Bristol Myers Squibb (2020). U.S. Food and Drug Administration Approves Onureg\u00ae (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia, Bristol Myers Squibb. Available online: https:\/\/news.bms.com\/news\/details\/2020\/U.S.-Food-and-Drug-Administration-Approves-Onureg-azacitidine-tablets-a-New-Oral-Therapy-as-Continued-Treatment-for-Adults-in-First-Remission-with-Acute-Myeloid-Leukemia\/default.aspx."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"107206","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.seminhematol.2015.03.002","article-title":"Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia","volume":"52","author":"Fathi","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/fon-2017-0523","article-title":"The role of IDH mutations in acute myeloid leukemia","volume":"14","author":"DiNardo","year":"2018","journal-title":"Future Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib inIDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1200\/JCO.2019.37.15_suppl.7028","article-title":"Ivosidenib (IVO.; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study","volume":"37","author":"Roboz","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: The next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3324\/haematol.2013.084434","article-title":"Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells","volume":"98","author":"Exalto","year":"2013","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3324\/haematol.2015.129577","article-title":"Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib\/II panobidara study","volume":"100","author":"Ocio","year":"2015","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrm1401","article-title":"Polo-like kinases and the orchestration of cell division","volume":"5","author":"Barr","year":"2004","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.18632\/oncotarget.23880","article-title":"Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia","volume":"9","author":"Gopalakrishnan","year":"2018","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/OTT.S60762","article-title":"Volasertib for AML: Clinical use and patient consideration","volume":"8","author":"Hao","year":"2015","journal-title":"Onco Targets Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"78452","DOI":"10.18632\/oncotarget.19632","article-title":"Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia","volume":"8","author":"Adachi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/38664","article-title":"Histone acetylation in chromatin structure and transcription","volume":"389","author":"Grunstein","year":"1997","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.breast.2018.12.001","article-title":"The role of histone deacetylase inhibitors in metastatic breast cancer","volume":"43","author":"Zucchetti","year":"2019","journal-title":"Breast"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/35057149","article-title":"A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms","volume":"409","author":"Sachidanandam","year":"2001","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1086\/342727","article-title":"Human diallelic insertion\/deletion polymorphisms","volume":"71","author":"Weber","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2008-07-169110","article-title":"Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia","volume":"113","author":"Kim","year":"2009","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.1182\/blood-2011-01-329797","article-title":"A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia","volume":"117","author":"Kim","year":"2011","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of Imatinib into and out of cells: Implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability","volume":"98","author":"Widmer","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","article-title":"OCT1 and imatinib transport in CML: Is it clinically relevant?","volume":"29","author":"Watkins","year":"2015","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J. Hum. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3109\/10428194.2014.893307","article-title":"Polymorphisms in the human organic cation transporter and the multidrug resistance gene: Correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia","volume":"55","author":"Vine","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","article-title":"Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)","volume":"20","author":"Nies","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1248\/bpb.34.114","article-title":"Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia","volume":"34","author":"Nambu","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose Imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2016.179","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","volume":"31","author":"Eadie","year":"2017","journal-title":"Leukemia"},{"key":"ref_66","first-page":"805","article-title":"Multidrug resistance protein expression in chronic myeloid leukemia: Associations and significance","volume":"86","author":"Giles","year":"1999","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.leukres.2016.10.005","article-title":"Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice","volume":"51","author":"Scheiner","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature22345","article-title":"Structure of the human multidrug transporter ABCG2","volume":"546","author":"Taylor","year":"2017","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/s41467-020-16155-2","article-title":"ABCG2 transports anticancer drugs via a closed-to-open switch","volume":"11","author":"Orlando","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"166980","DOI":"10.1016\/j.jmb.2021.166980","article-title":"Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2","volume":"433","author":"Kowal","year":"2021","journal-title":"J. Mol. Biol."},{"key":"ref_71","first-page":"6144","article-title":"Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib","volume":"116","author":"Deenik","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopha.2014.01.009","article-title":"Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients","volume":"68","author":"Au","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.18632\/oncotarget.1050","article-title":"High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients","volume":"4","author":"Delord","year":"2013","journal-title":"Oncotarget"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs-2016-0103","article-title":"Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: A meta-analysis","volume":"18","author":"Jiang","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of Imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bjh.12111","article-title":"The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of Imatinib in chronic myeloid leukaemia patients","volume":"160","author":"Katagiri","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/bloodadvances.2017006825","article-title":"ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure","volume":"1","author":"Marum","year":"2017","journal-title":"Blood Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12185-012-1142-6","article-title":"Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia","volume":"96","author":"Kong","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2133\/dmpk.DMPK-14-RG-031","article-title":"Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia","volume":"29","author":"Abumiya","year":"2014","journal-title":"Drug. Metab. Pharmacokinet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10147-013-0562-5","article-title":"Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia","volume":"19","author":"Shibata","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European Leukemia Net","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/pgs.12.103","article-title":"Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: The evolving role of Bcr\u2013Abl mutations and mutational analysis","volume":"13","author":"Soverini","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0091270003262101","article-title":"Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion","volume":"44","author":"Peng","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib","volume":"59","author":"Becker","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_90","unstructured":"FDA (2021). SCEMBLIX\u00ae (asciminib) Safely and Effectively."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2011","journal-title":"Med Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose Imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of Imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose Imatinib achieve better responses and have lower failure rates than those randomized to standard-dose Imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_97","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: Retrospective exposure-response analysis of a Phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-012-1998-4","article-title":"Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia","volume":"71","author":"Hsyu","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-10-1638","article-title":"The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia","volume":"16","author":"Kim","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/ijc.21666","article-title":"Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia","volume":"118","author":"Kim","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2217\/pgs-2016-0055","article-title":"Pharmacogenomics and the treatment of acute myeloid leukemia","volume":"17","author":"Montesinos","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_102","first-page":"201","article-title":"Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia","volume":"3","author":"Hampras","year":"2010","journal-title":"Int. J. Mol. Epidemiol. Genet."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","article-title":"Potential mechanisms of resistance to cytarabine in AML patients","volume":"26","author":"Galmarini","year":"2002","journal-title":"Leuk. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00008571-200411000-00007","article-title":"Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients","volume":"14","author":"Shi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00280-013-2258-y","article-title":"Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients","volume":"72","author":"Kim","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-12-3115","article-title":"Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy","volume":"19","author":"Mortland","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/tpj.2012.13","article-title":"Profiling of drug-metabolizing enzymes\/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin","volume":"13","author":"Iacobucci","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomized, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes-- report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/10\/1607\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:42:02Z","timestamp":1760143322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/10\/1607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":110,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jpm12101607"],"URL":"https:\/\/doi.org\/10.3390\/jpm12101607","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}